Fig. 7From: Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLCScore of patients’ quality of life. a All enrolled patients (p = 0.003). b Low dose group (p > 0.05). c Middle dose group (p > 0.05). d High dose group (p < 0.05). Each line represents one patient. Pre-Tx, pre-vaccination; Post-Tx,post-vaccinationBack to article page